ArriVent BioPharma, Inc. (AVBP) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $14.93 (-6.46%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jul 10, 2025 | Corinne Johnson | Goldman Sachs | $33.00 | +121.1% |
| Sep 10, 2024 | Yigal Nochomovitz | Citigroup | $36.00 | +141.2% |
| Sep 10, 2024 | Robert Burns | H.C. Wainwright | $36.00 | +141.2% |
| Aug 16, 2024 | Robert Burns | H.C. Wainwright | $30.00 | +101.0% |
| Jul 22, 2024 | Jeff Jones | Oppenheimer | $35.00 | +134.5% |
Top Analysts Covering AVBP
AVBP vs Sector & Market
| Metric | AVBP | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | +67.5% | +153002.0% | +21.5% |
| P/E Ratio | -6.95 | 3.48 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6M | $6M | $6M | 2 |
| 2027-03-31 | $15M | $15M | $15M | 1 |
| 2027-06-30 | $15M | $15M | $15M | 2 |
| 2027-09-30 | $15M | $15M | $15M | 2 |
| 2027-12-31 | $15M | $15M | $15M | 1 |
| 2028-12-31 | $127M | $131M | $135M | 8 |
| 2029-12-31 | $167M | $267M | $387M | 7 |
| 2030-12-31 | $271M | $434M | $630M | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.01 | $-1.01 | $-1.01 | 2 |
| 2027-03-31 | $-0.76 | $-0.76 | $-0.76 | 2 |
| 2027-06-30 | $-0.80 | $-0.80 | $-0.80 | 1 |
| 2027-09-30 | $-0.81 | $-0.81 | $-0.81 | 1 |
| 2027-12-31 | $-0.80 | $-0.80 | $-0.80 | 2 |
| 2028-12-31 | $-3.53 | $-1.47 | $1.86 | 6 |
| 2029-12-31 | $0.43 | $0.84 | $1.34 | 4 |
| 2030-12-31 | $1.82 | $3.54 | $5.63 | 2 |
Frequently Asked Questions
What is the analyst consensus for AVBP?
The consensus among 15 analysts covering ArriVent BioPharma, Inc. (AVBP) is Buy with an average price target of $22.00.
What is the highest price target for AVBP?
The highest price target for AVBP is $36.00, set by Yigal Nochomovitz at Citigroup on 2024-09-10.
What is the lowest price target for AVBP?
The lowest price target for AVBP is $30.00, set by Robert Burns at H.C. Wainwright on 2024-08-16.
How many analysts cover AVBP?
15 analysts have issued ratings for ArriVent BioPharma, Inc. in the past 12 months.
Is AVBP a buy or sell right now?
Based on 15 analyst ratings, AVBP has a consensus rating of Buy (2.00/5) with a +67.5% upside to the consensus target of $22.00.
What are the earnings estimates for AVBP?
Analysts estimate AVBP will report EPS of $-1.01 for the period ending 2026-12-31, with revenue estimated at $6M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.